Pacira BioSciences, Inc.
PCRX
$21.56
-$1.14-5.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.03M | 21.44M | -127.46M | -103.73M | -99.56M |
| Total Depreciation and Amortization | 91.02M | 85.42M | 89.99M | 81.53M | 78.79M |
| Total Amortization of Deferred Charges | 3.00M | 3.29M | 3.47M | 3.38M | 3.22M |
| Total Other Non-Cash Items | 89.21M | 101.17M | 220.33M | 212.55M | 218.04M |
| Change in Net Operating Assets | -38.27M | -69.88M | -51.80M | -17.98M | -11.10M |
| Cash from Operations | 151.99M | 141.44M | 134.52M | 175.75M | 189.39M |
| Capital Expenditure | -15.33M | -17.23M | -17.46M | -16.35M | -10.64M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -16.70M | -16.70M | -16.70M | -16.70M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.52M | 113.72M | 18.16M | -60.33M | -72.64M |
| Cash from Investing | 99.48M | 79.78M | -16.00M | -93.38M | -83.28M |
| Total Debt Issued | 101.00M | 101.00M | 0.00 | 287.50M | 287.50M |
| Total Debt Repaid | -317.80M | -315.61M | -12.19M | -210.89M | -210.89M |
| Issuance of Common Stock | 3.30M | 2.52M | 2.50M | 2.30M | 2.30M |
| Repurchase of Common Stock | -153.95M | -105.63M | -55.61M | -25.67M | -25.49M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.19M | -2.20M | 0.00 | -36.06M | -36.06M |
| Cash from Financing | -369.63M | -319.93M | -65.30M | 17.19M | 17.36M |
| Foreign Exchange rate Adjustments | -77.00K | 337.00K | 204.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -118.23M | -98.38M | 53.43M | 99.56M | 123.48M |